Last updated: 2026-09-09 05:05:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
GeneDx Holdings Corp. (WGS) operates in the SERVICES-HEALTH SERVICES sector and is listed on NASDAQ. The stock is currently priced at $85.83, with a market capitalization of $2.56B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $32.21 to $170.87. This page covers its latest market performance, valuation, price trends and company information.
$2.56B | |
$85.31 | |
$170.87 | |
$1.16 | |
$85.99 | |
369.08K | |
797.94K | |
-- | |
$170.87 | |
$32.21 | |
-- | |
-- |
GeneDx Holdings Corp. (WGS) last closed at $85.99 as of 2026-09-08 23:35:00, unchanged from the previous close of $85.99.
During the latest regular trading session, WGS traded between $1.16 and $170.87, with a volume of 369.08K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, GeneDx Holdings Corp. (WGS) moved from $89.24 to $85.83, representing a decline of 3.82% ($3.41).
The stock traded between $81.19 and $91.78 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 417.82 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 38.7%
WGS is currently trading at $85.83, placing it 38.7% of the way from its 52-week low of $32.21 to its 52-week high of $170.87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
| Industry | SERVICES-HEALTH SERVICES |
| Employees | 1300 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GeneDx Holdings Corp. (WGS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.